We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Athira Pharma Inc (ATHA) USD0.0001

Sell:$2.98 Buy:$2.99 Change: $0.20 (7.17%)
Market closed |  Prices as at close on 29 June 2022 | Switch to live prices |
Change: $0.20 (7.17%)
Market closed |  Prices as at close on 29 June 2022 | Switch to live prices |
Change: $0.20 (7.17%)
Market closed |  Prices as at close on 29 June 2022 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company's lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, blood brain barrier (BBB)-penetrating, small molecule HGF/MET positive modulator. The primary target indication is Alzheimers disease. The ATH-1017, is a subcutaneous administered, BBB-penetrating, small molecule hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) activator for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer's disease (AD). It also has preclinical candidates for non-AD indications, including ATH-1018, which is being developed to address peripheral indications, and ATH-1019/ATH-1020 compounds, which are being advanced to address neuropsychiatric indications. ATH technology is designed to promote HGF/MET activity for a variety of clinical applications.

Contact details

18706 North Creek Parkway
Suite 104, Box 352141
United States
+1 (425) 6208501

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$107.26 million
Shares in issue:
37.64 million
United States
US dollar

Key personnel

  • Mark Litton
    President, Chief Executive Officer, Director
  • Glenna Mileson
    Chief Financial Officer, Corporate Secretary
  • Rachel Lenington
    Chief Operating Officer, Chief Technology Officer, Head of Product Development Strategy
  • Kevin Church
    Vice President - Discovery
  • Hans Moebius
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.